公开(公告)号：KR100507814B1

公开(公告)日：2005-08-17

申请号：KR1020030006381

申请日：2003-01-30

Applicant: 한국과학기술원

Inventor： 정안식 ,  윤상오 ,  박수진 ,  김애영 ,  이호재

IPC: A61K31/352 ,  A61P35/04

Abstract: 본 발명은 메타쉐쿼이아의 잎으로부터 분리된 하기 구조식의 디하이드로히노키플라본 또는 이의 약제학적으로 허용되는 염을 활성성분으로 하는 항암제, 특히 암세포의 전이 및 침윤과 관련된 매트릭스메탈로프로티나아제(MMPs)의 발현을 감소시키고, p53의 활성화에도 관여하여 암세포의 성장, 전이 및 침윤을 억제하는 항암제를 제공한다.

公开(公告)号：KR1020040069834A

公开(公告)日：2004-08-06

申请号：KR1020030006382

申请日：2003-01-30

Applicant: 한국과학기술원

Inventor： 정안식 ,  윤상오 ,  박수진 ,  김애영 ,  이호재

IPC: A61K31/352 ,  A61P35/00

CPC classification number: A61K36/14 ,  A61K9/20 ,  A61K31/352 ,  A61K2236/33 ,  Y10S514/00

Abstract: PURPOSE: An anticancer drug comprising isoginkgetin or pharmaceutically acceptable salt thereof as an active ingredient is provided, thereby activating p53 and reducing a pathway of PI3-kinase/Akt, so that the growth of cancer cells can be inhibited. CONSTITUTION: The anticancer drug comprises Isoginkgetin isolated from leaves of Metasequoia glyptostroboides or pharmaceutically acceptable salt thereof as an active ingredient, wherein the anticancer drug activates p53 related to the cell cycle as a cancer inhibitor; the anticancer drug inhibits PI3-kinase/Akt signal pathway relating to cell death, so that death of cancer cells can be facilitated; and the anticancer drug increases sensitivity of cells to active oxygen species, so that it can be used together with conventional anticancer drug generating active oxygen species.

Abstract translation: 目的：提供作为活性成分的含有异糖凝胶蛋白或其药学上可接受的盐的抗癌药，由此激活p53并降低PI3激酶/ Akt的途径，从而能够抑制癌细胞的生长。 构成：抗癌药包含从水杉叶绿体叶片或其药学上可接受的盐中分离得到的等鞭毛虫作为活性成分，其中抗癌药物与细胞周期相关的p53作为癌症抑制剂活化; 抗癌药物抑制与细胞死亡相关的PI3-激酶/ Akt信号通路，从而可以促进癌细胞的死亡; 抗癌药提高了细胞对活性氧的敏感性，可以与常规的抗癌药产生活性氧一起使用。

公开(公告)号：KR1020040069833A

公开(公告)日：2004-08-06

申请号：KR1020030006381

申请日：2003-01-30

Applicant: 한국과학기술원

Inventor： 정안식 ,  윤상오 ,  박수진 ,  김애영 ,  이호재

IPC: A61K31/352 ,  A61P35/04

CPC classification number: A61K36/14 ,  A61K9/20 ,  A61K31/353 ,  A61K2236/33 ,  Y10S514/00

Abstract: PURPOSE: An anticancer drug comprising dihydrohinokiflavone or pharmaceutically acceptable salt thereof as an active ingredient is provided, thereby reducing the expression of matrixmetalloproteinase(MMPs) related to metastasis and invasion of cancer cells, and activating p53. CONSTITUTION: The anticancer drug comprises dihydrohinokiflavone isolated from leaves of Metasequoia glyptostroboides or pharmaceutically acceptable salt thereof as an active ingredient, wherein the anticancer drug reduces the expression of matrixmetalloproteinase(MMPs) related to metastasis and invasion of cancer cells, the anticancer drug activates p53 related to a cancer inhibitor; and the anticancer drug increases sensitivity of cells to active oxygen species, so that it can be used together with conventional anticancer drug generating active oxygen species.

Abstract translation: 目的：提供包含二氢in藜酮或其药学上可接受的盐作为活性成分的抗癌药物，从而降低与癌细胞的转移和侵袭有关的基质金属蛋白酶（MMP）的表达，并激活p53。 构成：抗癌药包含从水杉叶绿体叶片或其药学上可接受的盐中分离的二氢in藜酮作为活性成分，其中抗癌药降低了与癌细胞转移和侵袭相关的基质金属蛋白酶（MMPs）的表达，抗癌药物激活p53相关 对癌症抑制剂; 抗癌药提高了细胞对活性氧的敏感性，可以与常规的抗癌药产生活性氧一起使用。